Citations

Clear

196 citation(s) found for "Schultz, M".

Targeted long-read RNA sequencing for rare disease diagnosis and variant interpretation
Wang, Robert , Wang, Feng , DeBruyne, Nicole , Ji, Xinjun , Engelhardt, Nicole , Park, Joseph Jee-Hwan , Notaro, Amber , Gaerlan, Samantha , Park, Ryan , Schultz, Matthew J, Clever, Sheila, Keith, Kelsey , Ng, Bobby G. , Kadash-Edmondson, Kathryn E. , Freeze, Hudson H. , Lam, Christina , Morava, Éva , Helbig, Ingo , Falk, Marni J. , Ganetzky, Rebecca , Edmondson, Andrew C. , Lin, Lan , Xing, Yi , Engelhardt, Nicole M , Schultz, Matthew J , McCormick, Elizabeth M , Keith, Kelsey , Ng, Bobby G , Kadash-Edmondson, Kathryn E , Freeze, Hudson H , Lam, Christina , Morava, Eva , Helbig, Ingo , Falk, Marni J , Ganetzky, Rebecca D , Edmondson, Andrew C , Lin, Lan , Xing, Yi

Mayo Clinic

Science Advances | April 15, 2026 | Volume: 12 | Issue: 16 | Pages: No page available

10.1126/sciadv.ady9895 | PMID 41984969 Get It

Diagnosing rare genetic diseases remains a major challenge despite widespread clinical testing. Long-read RNA sequencing (RNA-seq) offers a powerful approach to capturing the effects of genetic variants on the transcriptome, yet challenges with sequencing coverage, cost, tissue selection, and scalability have limited its clinical adoption. To address this, we developed STRIPE (Sequencing Targeted RNAs Identifies Pathogenic Events), a targeted long-read RNA-seq–based strategy for rare disease diagnosis and variant interpretation. STRIPE enables deep sequencing of full-length transcripts for any customized disease-specific gene panel such that a wide range of clinically informative readouts, including transcript aberrations and sequence variants, can be detected at haplotype-level resolution. Applying STRIPE to 88 individuals spanning two major rare disease groups, we accurately reidentified known pathogenic variants and revealed their transcript consequences, including many unexpected ones. For 8 of 15 splice site region variants, we observed more complex RNA processing defects beyond single exon skipping or cryptic splice site activation. Notably, we find that donor splice site variants frequently activate cryptic intronic polyadenylation sites, leading to premature transcript termination. Leveraging unique strengths of long-read RNA-seq, STRIPE also resolved variants of uncertain significance and uncovered disease-causing variants in five previously undiagnosed individuals. Overall, STRIPE is a powerful, adaptable, and scalable strategy with broad potential to improve clinical variant interpretation and advance genetic diagnosis of rare diseases.
International development of Investigator Global Assessment scores for pemphigus
Murrell, Dédée F., Boucher, Darby , Daneshpazhooh, Maryam, Mahmoudi, H., Kianfar, Nika , Wilson, Anna , BILGIC, ASLI, Chandran, N. S., Patsatsi, Aikaterini , Caux, Frédéric, Lim, Yen L., Marzano, Angelo V., Payne, Aimee S., Sprecher, Eli, Beek, Nina Van, Yamagami, Jun , Antiga, Emiliano, Bagci, I., Borradori, Luca, Caproni, Marzia, De, Dipankar, Dunn, Patrick F. , Feliciani, Claudio, Fivenson, David , Handa, Sanjeev, Horvath, B., Ioannides, D. , Kasperkiewicz, Michael, Lipman, Rachel E. , Mascaró, José M., Meijer, Joost M. , MIMOUNI, D, Schultz, Brittney , Skiljevic, Dusan, Strong, Becky, Tomayko, Mary M. , Vestergaard, Christian , Wozniak, Katarzyna, Yayli, S., Joly, Pascal, Werth, Victoria P., Caproni, Marzia , Joly, P. , Horváth, Barbara , Murrell, D F , Daneshpazhooh, M , Mahmoudi, Hamidreza , Wilson, Anna , Patsatsi, Aikaterini , Drenovska, Kossara , Caux, Frédéric , Marzano, Angelo Valerio , Schmidt, Enno , Sprecher, Eli , Van Beek, Nina , Antiga, Emiliano , Borradori, Luca , Caproni, Marzia , Feliciani, Claudio , Ioannides, Dimitrios , Kasperkiewicz, Michael , Mascaró, José M , Meijer, Joost M , Schultz, Brittney , Vestergaard, Christian , Joly, Pascal , Dasdar, Shayan , Yale, Marc , Uzun, Soner , Vassileva, Snejina , Culton, Donna Aline , Hertl, Michael , Marinović, Branka , Marzano, Angelo Valerio , Payne, Aimee S. , Schmidt, Enno , Sprecher, Eli , Bağci, Işın Sinem , Corrà, Alberto , De, Dipankar , Dunn, Patrick, Günther, Claudia , Handa, Sanjeev , Kowaléwski, Cezary , Lehman, Julia S. , Mimouni, Daniel , Skiljevic, Dusan S. , Woźniak, Katarzyna , Yaylı, Savaş , Werth, Victoria P.

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | April 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/jdv.70430 | PMID 41944632 Get It

Extensive Hypoglycosylation of Serum N‐Glycoproteins in SRD5A3 Deficiency
Jain, Anu, Garapati, Kishore , Lam, Christina , Kozicz, T., Morava, Eva, Pandey, Akhilesh , Kozicz, Tamás , Garapati, Kishore , Lam, Christina , Kozicz, Tamas , Pandey, Akhilesh , Budhraja, Rohit , Schultz, Matthew , Morava, Éva

Mayo Clinic

Journal of Inherited Metabolic Disease | March 9, 2026 | Volume: 49 | Issue: 2 | Pages: No page available

10.1002/jimd.70163 | PMID 41732066 Get It

ABSTRACT Polyprenal reductase is an enzyme encoded by the SRD5A3 gene, which is involved in the synthesis of dolichol from polyprenol. Dolichol serves as a carrier for glycan precursors or monosaccharides in N‐linked glycosylation. Pathogenic variants in SRD5A3 can result in a congenital disorder of glycosylation (CDG), SRD5A3‐CDG, which is inherited in an autosomal recessive manner. Most plasma proteins are glycosylated and changes in the glycosylation of several glycoproteins are associated with pathological consequences. Despite the critical role of SRD5A3 in glycosylation, the impact of its deficiency on the glycosylation of serum proteins remains largely unexplored. In this study, we used tandem mass tag‐based multiplexed quantitative approach to analyze serum N‐glycoproteomics and proteomics in SRD5A3‐CDG patients and controls. We quantified 2200 serum N‐glycopeptides from 359 N‐glycosites from 204 serum proteins. Extensive hypoglycosylation of serum proteins was observed in patients, with 245 of 291 altered glycopeptides decreased in SRD5A3‐CDG. Altered glycopeptides included those derived from haptoglobin, plasma serine protease inhibitor, alpha‐1‐B glycoprotein, alpha‐2‐macroglobulin, and ceruloplasmin. Some of these proteins have previously been reported to be associated with liver dysfunction, anemia, and coagulopathy, which could underlie similar clinical features observed in SRD5A3‐CDG patients. Overall, our study provides novel insights into alterations in the glycosylation status of specific serum proteins in SRD5A3‐CDG. Some of these alterations could be further pursued to develop glycopeptide‐based biomarkers as the current diagnosis of SRD5A3‐CDG by screening assays remains challenging. In addition, knowledge of altered glycoproteins could enhance our understanding of the disease spectrum and potentially unveil additional therapeutic avenues.
Factors Affecting Outcomes of Hindfoot Fusion Nails for Acute Injury: A Multicenter Study
Kim, Eugene , Tornetta, Paul , Carlson, Jon, Schultz, Alex, Wireman, Garrett , Ollivere, Benjamin J., Zheng, Amy , Patch, David , White, Tim D. , Heinz, Nicholas , Lahurd, Caroline Elizabeth, Ostrum, Robert F. , Baumann, Charles, Kottmeier, Stephen, Doany, Michael E. , Krause, Peter, Redlich, Nathan, Egol, Kenneth, Konda, Sanjit, Mir, Hassan, McCaskey, Meghan , Azer, Emil, Kusler, Jace E. , Beltran, Michael T., Mehta, Samir, Masada, Kendall M. , Hidden, Krystin A., Kuttner, Nicolas P. , Tornetta, Paul , Beltran, Michael J. , Kuttner, Nicolas, Schultz, Alexander , Ollivere, Ben J. , Zheng, Amy, Spitler, Clay A. , White, Tim, Stinner, Daniel J. , Baumann, Charles A. , Krause, Peter C. , Egol, Kenneth A. , Konda, Sanjit R. , Beltran, Michael, Mehta, Samir D. , Hidden, Krystin A.

Mayo Clinic

Journal of Orthopaedic Trauma | February 13, 2026 | Volume: 40 | Issue: 3 | Pages: 148-154

10.1097/bot.0000000000003104 | PMID 41685944 Get It

OBJECTIVE: To evaluate the effect of joint preparation and patient factors on outcomes and complications in patients treated acutely with hindfoot fusion nails for ankle and pilon fractures. METHODS: Design: Retrospective chart review. Setting: Thirteen US trauma centers and 2 UK trauma centers. Patient Selection Criteria: Ankle and pilon fractures (AO-OTA types A-C) from 2010 to 2020 acutely treated definitively with hindfoot fusion nail were reviewed. Patients at least 18 years old and with minimum 6 months follow-up or earlier diagnosis of complication were included. Exclusion criteria included nonambulatory at baseline, prior internal fixation that failed and underwent revision, and prior tibiotalar or subtalar arthrodesis. Outcome Measurements and Comparisons: The primary outcome was final postoperative ambulatory status. Secondary outcomes were infectious and fracture-related complications. RESULTS: One hundred forty-nine patients (75 men; 74 women; age 20–99; median 63 years) were treated for ankle (104) or pilon (45; 8A, 13B, 24C) fractures. Eighty-five patients (44%) had open fractures and 55 (37%) had diabetes. Thirty-six patients (24%) had joint preparation at the time of surgery. Forty-five (30%) were made weight bearing as tolerated postoperatively; the median time to mobilize was 1.5 days (0–210) and to full weight bearing was 35 days (0–1462). Fifty-seven patients (85%) returned to their preinjury ambulatory status, which was not affected by joint preparation (50% vs. 59%, P = 0.327). Joint preparation led to higher articular fusion rates (94% vs. 24%; P = 0.001) and fewer hardware removals (19% vs. 42%, P = 0.013), but trended toward a higher fracture nonunion rate (19% vs. 8%, P = 0.053). Forty-five patients (30%) had infectious complications, 60 (40%) had a fracture-related complication, and 67 (45%) had additional procedures. Open fractures did not lead to any differences in superficial or deep infection. Insulin-dependent diabetes was associated with higher rates of infectious complications (31% vs. 15%, P = 0.028) and amputation (17% vs. 4%, P = 0.029). CONCLUSIONS: Hindfoot fusion nails for acute ankle and pilon injuries had high complication rates. More complications occurred in patients with insulin-dependent diabetes. While 95% regained ambulation, only 57% returned to preoperative status. Joint preparation led to higher rates of articular fusion (94% vs. 24%, P < 0.001) but not fracture union (81% vs. 66%, P = 0.106). LEVEL OF EVIDENCE: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.
Abstract A013: Genomic prognostic biomarkers in prostate cancer from the AACR GENIE cohort
Morgado, Pablo Cresta , Vilacampa, Guillermo, Alatoom, Haitham, Rio, Manuel Ramos del, Sweeney, Shawn M. , Schultz, N., Kehl, Ken, Riely, G., Abida, Wasim, Panageas, Katherine S. , Bédard, Philippe L. , Micheel, Christine, Guo, Xindi, Nayan, Chelsea, Dientsmann, R., Mateo, Joaquin, Navarro, Victor, Riaz, Irbaz Bin , Schultz, Nikolaus D. , Kehl, Kenneth L. , Riely, Greg J., Schrag, Deborah , Micheel, Christine , Mateo, Joaquı́n

Mayo Clinic

Cancer Research | January 20, 2026 | Volume: 86 | Issue: 2_Supplement | Pages: A013-A013

10.1158/1538-7445.prostateca26-a013 Get It

Abstract INTRODUCTION: Prostate cancer (PC) shows marked heterogeneity in clinical outcomes, from indolent to highly aggressive disease. Alterations in TP53, PTEN, RB1, and DNA damage repair genes are linked to poor patient outcomes, yet how the interaction and co-occurrence of these alterations impact prognosis remains unclear. We leveraged the AACR Project GENIE prostate cancer cohort to assess the prognostic impact of individual and concomitant gene alterations, focusing on key PC drivers (BRCA2, TP53, PTEN, RB1). METHODS: the study was conducted in two stages: (i) identification of candidate alterations at individual gene level through a systematic literature review, followed by analyzing the prevalence and co-occurrence of genes in the AACR Project GENIE Public Release (PR) dataset. (ii) Prognostic analysis of the pre-selected biomarkers in the AACR Project GENIE Biopharma Collaborative (BPC) cohort. Analyses were performed in three clinical settings (entire BPC cohort, n=1114; subgroup of patients with localized disease at diagnosis, n=837; and subgroup of patients with metastatic PC with a biopsy collected before or at the time of mPC, n=455) using two statistical approaches: univariate analysis (UA) and inverse probability weighting using propensity scores (PS). Cox models were applied to estimate overall survival hazard ratios (HRs). RESULTS: after integrating the findings from the systematic review with the analysis of the GENIE PR (n=5684), 107 individual genes and 122 co-occurring alterations were selected for study. In the GENIE BPC (n=1114 patients) 75% were M0 at diagnosis, and 67% presented metastatic PC at any time. Alteration prevalence was: TP53, 25%; PTEN, 15%; BRCA2, 4%; RB1, 4%; co-alterations included, PTEN-TP53 (6.4%), RB1-TP53 (2.1%), PTEN-RB1 (1.3%), and BRCA2-TP53 (1.2%). All four key genes showed a statistically significant prognostic impact in the entire cohort with UA (BRCA2, HR:1.9; TP53, HR:2.6; PTEN, HR:2.4; RB1, HR:4.1, all p&lt;0.001). Results were consistent in the subgroup analysis and when using PS. Additional genes such as FANCA, PIK3CA, and MYC were also associated with poor outcomes. Among co-alterations, BRCA2-TP53 (HR:2.0, p=0.05), RB1-TP53 (HR:3.6, p&lt;0.001), PTEN-TP53 (HR:2.4, p&lt;0.001); PTEN-RB1 (HR:5.5, p&lt;0.001), and PTEN-TP53-RB1 (HR:9.0, p&lt;0.001) were the strongest predictors of poor survival, with consistent effects across subgroups and analytical methods. Other combinations including MYC-TP53 (HR 2.2, p&lt;0.001) and PIK3CA-TP53 (HR 3.2, p&lt;0.001), also showed independent prognostic value. CONCLUSIONS: Genomic alterations in TP53, PTEN, RB1, and BRCA2, alone and in combination, independently associate with poor prognosis. Co-alteration patterns such as PTEN-TP53-RB1 define aggressive molecular subsets. This evidence supports integrating genomic interaction patterns for enhancing clinical risk models and guiding precision patient management. Furthermore, this study highlights the potential of AACR Project GENIE to enable data-driven development of biomarker-informed patient care strategies. Citation Format: Pablo Cresta Morgado, Victor Navarro, Guillermo Vilacampa, Haitham Alatoom, Manuel Ramos del Rio, Irbaz Riaz, Shawn Sweeney, Nikolaus Schultz, Ken Kehl, Gregory Riely, Wasim Abida, Katherine Panageas, Deborah Schrag, Philippe Bedard, Christine Micheel, Xindi Guo, Chelsea Nayan, Rodrigo Dientsmann, Joaquin Mateo. Genomic prognostic biomarkers in prostate cancer from the AACR GENIE cohort [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Innovations in Prostate Cancer Research and Treatment; 2026 Jan 20-22; Philadelphia PA. Philadelphia (PA): AACR; Cancer Res 2026;86(2_Suppl):Abstract nr A013.
Plasma levels of an N‐terminal tau fragment predict Alzheimer's and neurodegenerative disease biomarkers in autosomal dominant Alzheimer's disease
Liu, L, Ostaszewski, Beth L., Anderson, Amirah K. , Yau, Wai‐Ying Wendy , Shirzadi, Zahra , Gordon, Brian A., Hassenstab, Jason, Morris, J. Newman, Perrin, Richard J., Allegri, Ricardo F., Barthélemy, Nicolas R., Fox, Nick, Day, Gregory S., Jucker, Mathias, Levey, Allan I., Levin, Johannes, Mori, Hiroshi, Salloway, Stephen, Schofield, Peter, McDade, DO Eric, Sperling, Reisa A., Bateman, Randall J., Selkoe, Dennis J., Chhatwal, Jasmeer P., Network, and the Dominantly Inherited Alzheimer's, Xiong, Chengjie , Hassenstab, Jason , Xiong, Chengjie , Hassenstab, Jason , Schultz, Stephanie A. , Rao, Yiwen, Liu, Lei, Gordon, Brian A. , Perrin, Richard J. , Allegri, Ricardo , Barthélemy, Nicolas R. , Day, Gregory S. , Jucker, Mathias , Levey, Allan I. , Salloway, Stephen , Schofield, PR, McDade, Eric , Sperling, Reisa Anne , Bateman, Randall J. , Selkoe, Dennis J. , Chhatwal, Jasmeer P.

Mayo Clinic

Alzheimer's & Dementia | January 8, 2026 | Volume: 22 | Issue: 1 | Pages: No page available

10.1002/alz.71049 | PMID 41505233 Get It

Abstract INTRODUCTION Tau species lacking truncation of the N‐terminal region, including plasma N‐terminal tau fragment 1 (NT1), have been previously associated with cognitive decline, neurodegeneration, and tau pathology in late‐onset sporadic Alzheimer's disease (AD). METHODS Here, we examined cross‐sectional and longitudinal plasma NT1 as a possible predictor of cognitive, clinical, and core AD biomarker trajectories in autosomal dominant AD (ADAD). RESULTS NT1 levels in ADAD mutation carriers (MC; n = 132) increased across the disease continuum, compared to non‐carriers (NC; n = 75), becoming elevated about a decade prior to estimated symptom onset. Cross‐sectional and longitudinal NT1 levels in MC were associated with clinical, cognitive, and biomarker changes. NT1 increases continued in symptomatic phases of disease, a distinct trajectory from that seen with CSF p‐tau217 and other phospho‐tau species. DISCUSSION Together, our results suggest that plasma NT1—alone or combined with other tau measures—may be useful in studying AD‐related clinical, cognitive, and biomarker outcomes. Highlights Leveraging a deeply phenotyped cohort of individuals carrying a pathogenic variant for autosomal dominant Alzheimer's disease (ADAD) and their non‐carrier family members, our results suggest that plasma N‐terminal tau fragment 1 (NT1) levels mirrored changes in clinical, cognitive, and neurodegenerative measures in ADAD, particularly in late asymptomatic and early symptomatic phases of disease. NT1 levels correlated with cerebrospinal fluid (CSF) measures of tau pathology but less so with CSF or imaging measures of β‐amyloid pathology. Together with previous supportive findings in preclinical and symptomatic sporadic AD, these results suggest that plasma NT1—alone or combined with other tau measures—may be useful in studying AD‐related tau pathology and neurodegeneration across a wide spectrum of disease.
Validation of Amyloid Chronicity in Autosomal Dominant Alzheimer Disease
Christian, Bradley T, Schultz, Stephanie A. , Barthélemy, Nicolas R., Ryan, Natalie S. , Renton, Alan E., Vermunt, Lisa, Joseph‐Mathurin, Nelly, Shirzadi, Zahra , Strain, Jeremy F. , Chrem, Patricio, Daniels, Alisha , Chhatwal, Jasmeer P. , Cruchaga, Carlos, Ibanez, Laura, Jucker, Mathias, Day, Gregory S, Lee, J.R, Supnet‐Bell, Charlene, Xiong, Chengjie, Schindler, Suzanne E., Wang, Guoqiao, Li, Yan, Koeppe, Robert A., Jack, Clifford R., Morris, John C., Bateman, Randall J., Benzinger, Tammie L.S., Gordon, Brian A., (DIAN), The Dominantly Inherited Alzheimer Network, Wisch, Julie K. , McKay, Nicole S. , Zammit, Matthew D. , Christian, Bradley T. , Millar, Peter R , Barthélemy, Nicolas R. , Renton, Alan , Vermunt, Lisa , Joseph‐Mathurin, Nelly , Cruchaga, Carlos , Ibanez, Laura , Jucker, Mathias , Day, Gregory S. , Xiong, Chengjie , Llibre‐Guerra, Jorge J. , Aguillon, David , Roh, Jee Hoon , Xiong, Chengjie , Schindler, Suzanne E. , Wang, Guoqiao , Li, Yan , Koeppe, Robert A., Jack, Clifford R. , Morris, John C. , McDade, Eric , Bateman, Randall J. , Benzinger, Tammie L.S. , Ances, Beau M. , Betthauser, Tobey J. , Gordon, Brian A.

Mayo Clinic

Alzheimer's & Dementia | December 26, 2025 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_103008 Get It

Abstract Background Alzheimer Disease (AD) pathology evolves over decades, and understanding this progression is critical to the understanding of the disease and timing therapeutic interventions. Since individuals with Autosomal Dominant AD (ADAD) develop symptoms around the same age as their parent, it is possible to predict symptom onset and stage individuals by their estimated years to symptom onset (EYO). This approach does not generalize to other forms of AD, thus there is a pressing need for the timecourse of ADAD to be defined in broadly relevant terms. The objective of this project is to validate the Sampled Iterative Local Approximation (SILA) algorithm in a cohort with a known disease timecourse. SILA generates an estimate of time from amyloid positivity (A time ) based on longitudinal PET data. Method We evaluated A time in a longitudinal ADAD sample ( N = 316) with PET PiB data in three ways. First, we compared predicted age at amyloid positive (A+) to observed age at A+ for individuals who became A+ during enrollment. Next, using linear regression, we compared estimated age at A+ to estimated age at symptom onset (EYO=0). Finally, we used generalized additive models to compare the amount of variance in concurrent cognitive performance explained both A time and EYO. Result We observed a mean average error of 1.15 years between actual age at A+ ( N = 26) and the SILA‐predicted A time . Across all participants, SILA‐estimated age at A+ explained 39% of the variance in estimated age at symptom onset ( β = 0.918, p < 0.0001). Finally, we observed a nonlinear association between cognition and both A time and EYO. A time explained 19% of the variance in the general cognitive composite while EYO explained 43% of the variance. Conclusion SILA produces a valid estimate of time‐from‐amyloid positivity in ADAD. This work allows for disease stage in ADAD to be compared to staging for broad forms of AD, which was not previously possible using EYO. However, this work also illustrates that there is a high degree of heterogeneity in preclinical disease duration that is not explained by amyloid alone.
Multicenter assessment of absolute neutrophil counts (ANC) and white blood cell counts (WBC) in healthy participants with the erythrocyte duffy null phenotype or genotype
Attipoe, Gilles, Blechner, Michael, Cuker, Adam , Fadeyi, Emmanuel A. , Forbes, Victoria , Francischetti, Ivo M.B. , Gadi, Vijayakrishna K. , Haimed, Abraham , Han, Hyojeong , Haspel, Richard L. , Karafin, Matthew S. , Klein, Kimberly, Kumar, Priyadarshini , Kushnir, Margarita , Lewis, Michael R. , Li, Geling , Brzostek, Sabrina, Rose, Gary S. , Siddon, Alexa J. , Sillings, Christine N., Soni, Amy , Stevens, Don A., Szymanski, James , Takemoto, Clifford M., Warsame, Rahma , Zaghloul, Nibal, Belay, Yadashe, Fink, Aliza K., Frustace, Patricia, Tyson, Jamie, Havre, Nathalie van , Achebe, Maureen , Merz, Lauren E. , Barriteau, Christina M. , Blechner, Michael, Burks, Eric , Calhoun, Cecelia L. , Campbell-Lee, Sally , Chang, Vivian Y. , Chou, Stella T. , Fingrut, Warren , Godby, Richard , Godley, Lucy A. , Ilonze, Chibuzo , Jacquot, Cyril , Ji, Peng Cheng , Juskewitch, Justin E. , Kucine, Nicole , Levitz, David , Lewis, Michael, Mei, Zhen W. , Rose, Gary, Schultz, Corinna L. , Sloan, J. Mark , Story, Charlotte McIlwaine , Thompson, Alexis A. , Weyand, Angela C. , Wilson, Samuel , Belay, Yadashe, Tyson, Jamie

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 1074-1074

10.1182/blood-2025-1074 Get It

Abstract Introduction: The Duffy null variant (genotype or phenotype) is associated with lower circulating absolute neutrophil counts (ANC) without increased risk for infection. It is found in ~66% of people identifying as Black or African American vs &lt;1% of people of Asian or European ancestry. Many ANC reference intervals (RI) are not representative of the Duffy null population. There are no adult Duffy null WBC RI and no pediatric Duffy null ANC or WBC RI. Thus, we aimed to assess Duffy null ANC and WBC distributions as well as develop WBC and ANC RI for adults and pediatrics. Methods: Twenty-three sites across the United States collected samples with all sites excluding participants with conditions or medications that could impact ANC or WBC. Only Duffy null participants were included. Sex, race, ethnicity, age, sample collection type, practice setting, Duffy testing method, ANC, and WBC were recorded. The non-parametric method for determining lower limit of normal (LLN), upper limit of normal (ULN), and 90% confidence intervals (CI) around the limits was performed according to the Clinical and Laboratory Standards Institute guidelines. Specific ULN and LLN are not reported as these are preliminary data. The Mann-Whitney U test was used to compare sex and prior data; differences by age groups were assessed with Kruskal-Wallis test. Results: 316 participants 18+ years-old (y/o) were assessed of whom 62.3% (n=197) are female, 97.5% (n=308) identified as Black or African American, and 94.9% (n=300) identified as non-Hispanic. Median age was 47 y/o (IQR: 32-60.5). Median ANC was 2600/uL (IQR: 1860-3530; range: 400-7400); 28.6% (n=90) of participants had ANC &lt;2000/uL, 13.6% (n=43) had ANC &lt;1500/uL, and 2.5% (n=8) had &lt;1000/uL. The 90% CI around the LLN was 810-1070/uL and 5570-7130/uL around the ULN. Consistent with prior data, there was a difference in median ANC by sex (male: 2400/uL; female: 2710/uL; p=0.02). There was no significant difference between this ANC data and previously published Duffy null ANC data (p=0.28). Median WBC was 5.4x109/L (IQR: 4.4-6.5; range: 2.10-11.64) with 4.1% (n=13) of participants with WBC &lt;3.0x109/L. The 90% CI around the LLN is 3.68-4.30x109/L and 11.02-12.97x109/L around the ULN. 515 participants between 0-17 y/o were assessed with 51.8% (n=267) females, 94.8% (n=488) identified as Black or African American, and 94.0% (n=484) identified as non-Hispanic. Among pediatric participants, 56.8% (n=291) had ANC &lt;2000/uL, 38.7% (n=198) had ANC &lt;1500/uL, and 14.4% (n=74) had ANC &lt;1000/uL. For those &lt;1 y/o (n=29), median ANC was 950/uL (IQR: 840-1360; range: 111-3910). There are currently too few samples to predict ULN and LLN. Median WBC was 8.85x109/L (IQR: 7.03-10.16; range: 4.17-13.53). For those 1-5 y/o (n=143), median ANC was 1735/uL (IQR: 1100-2550; range: 207-5810) with a 90% CI around the LLN of 207-820/uL and 4020-5810/uL around the ULN. Median WBC was 6.72x109/L (IQR: 5.64-8.25; range: 3.68-12.97). For those 6-11 y/o (n=128), median ANC was 1590/uL (IQR: 1090-2470; range: 420-5490) with a 90% CI around the LLN of 420-910/uL and 4340-5490/uL around the ULN. Median WBC was 5.42x109/L (IQR: 4.45-6.70; range: 2.80-10.50). For those 12-17 y/o (n=215), median ANC was 2190/uL (IQR: 1460-2930; range: 204-5850) with a 90% CI around the LLN of 540-930/uL and 4350-5510/uL around the ULN. Median WBC was 5.06x109/L (IQR: 4.26-6.20; range of 2.04-9.91). There is a significant difference in ANC by age category (p&lt;0.0001). Conclusion: This is the first report of healthy pediatric Duffy null ANC and WBC data and the first large-scale verification of adult Duffy null ANC and WBC data. Final RI are expected in September 2025. Among adults with the Duffy null phenotype, ANC LLN are likely between 810-1070/uL. Pediatric ANC LLN are likely as low as 207-820/uL (1-5 y/o), 420-910/uL (6-11 y/o), and 540-930/uL (12-17 y/o). These findings redefine “normal” as a significant proportion of healthy participants have ANC or WBC below current RI or below thresholds typically defined as disease. Limitations include heterogeneous sample populations and collection methods. Future analyses will assess differences between collection sites or methods. Ultimately, this work lays the foundation for a more scientifically sound and equitable approach to medical care by ensuring that RI accurately reflects health for the entire community. Healthcare systems are strongly encouraged to adopt Duffy null-specific ANC and WBC RI.
The Weekend Effect on Evidence-Based Care Adherence Before and After Implementation of Checklist-Based Care in the Intensive Care Unit: A Multinational Study
Tekin, Aysun , Swart, Pien , Schultz, Marcus J. , Gajic, Ognjen, Network, for the CERTAIN investigators of the Society of Critical Care Medicine Discovery, Flurin, Laure , Schultz, Marcus J , Tekin, Aysun , Vukoja, Marija , Kashyap, Rahul , Gajic, Ognjen , Dong, Yue , Network, for the CERTAIN investigators of the Society of Critical Care Medicine Discovery

Mayo Clinic

Journal of Intensive Care Medicine | November 24, 2025 | Volume: 41 | Issue: 7 | Pages: 660-669

10.1177/08850666251396016 | PMID 41284657 Get It

Background Adherence to evidence-based care processes and patient outcomes in intensive care units (ICUs) can be influenced by staffing and resource availability. We aimed to evaluate if there is a weekend effect on adherence to evidence-based care processes, and hospitalization outcomes and whether a checklist implementation could mitigate potential differences. Methods Post hoc analysis of the Checklist for Early Recognition and Treatment of Acute Illness and Injury (CERTAIN) study dataset collected before and after checklist implementation in 34 ICUs across 15 countries (2013-2017). Admission days were classified as ‘weekend/holidays’ or ‘weekdays’ according to local work schedules and public holidays. The primary outcome was the omission of 10 evidence-based care processes addressed in the checklist. Mortality and length of stay differences between weekend/holiday and weekday admissions were evaluated as secondary outcomes. Results 4256 patients contributed 1141 weekend versus 3501 weekday observation days pre-intervention, and 2014 versus 6507 post-intervention. Pre-intervention, peptic ulcer prophylaxis was omitted more frequently on weekends/holidays than weekdays (adjusted rate ratio [aRR], 0.58 [95%–confidence interval [CI] 0.38-0.88), whereas head-of-bed elevation was omitted more often on weekdays than on weekends/holidays (aRR, 3.17 [1.14-8.86]). Post-intervention, peptic ulcer prophylaxis omission rates became similar (aRR, 1.03 [0.68-1.56], but head-of-bed elevation became omitted more often on weekends than on weekdays (aRR, 0.63 [0.45-0.88]). Post-intervention, oral care was omitted more frequently on weekends/holidays than in weekdays (aRR, 0.63 [0.45-0.9]), and central catheter removal was more frequent on weekdays than in weekends/holidays (aRR, 1.11 [1.02-1.21]). No significant differences in mortality or length of stay were found. Conclusion A weekend effect influenced adherence to some care processes. While checklist implementation improved overall adherence, some disparities diminished, while new ones emerged. Organizational, cultural, and temporal factors should be further studied to optimize care delivery across all times and settings. Clinical Trial Registration Number NCT01973829
Efficacy and Safety of Varied Bisphosphonate Therapy Dosing in Patients With Hypercalcemia of Malignancy
Schultz, Sydney , Barreto, Jason N. , Cole, Kristin C., Wang, Yucai , Choong, Grace M. , Leung, Nelson , Schultz, Sydney E , Leung, Nelson , Wang, Yucai , Choong, Grace M , Cole, Kristin C.

Mayo Clinic

JCO Oncology Practice | November 21, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/op-25-00543 | PMID 41270242 Get It

PURPOSE The difference in time to serum calcium normalization and rates of subsequent refractory hypocalcemia between bisphosphonates requires further investigation. Our primary objective was to assess the difference in normalization of serum calcium between pamidronate and zoledronic acid during treatment of hypercalcemia of malignancy (HCM) and rates of subsequent, refractory hypocalcemia following therapy. METHODS A retrospective review of patients with cancer who received pamidronate or zoledronic acid inpatient at Mayo Clinic for treatment of HCM between January 2018 and January 2024 was conducted. Logistic regression evaluated the association between treatment groups and outcomes. Multivariable modeling was adjusted for baseline differences, including severity of hypercalcemia. RESULTS We evaluated 856 patients. The median age was 68 (IQR, 59-75) years, and 476 (55.6%) were male. The most common cancer diagnoses were lymphoma (n = 158, 18.5%), followed by multiple myeloma (n = 145, 16.9%) and lung cancer (n = 111, 13%). Overall, 292 (46.8%) patients and 154 (32.8%) patients achieved serum calcium normalization by hospital day 4 and day 7, respectively. The rate of normalization was similar between all bisphosphonates, regardless of pamidronate dose. Significantly higher rates of hypocalcemia were observed on day 4 for patients who received zoledronic acid 4 mg once compared with either dose (60 mg once and 90 mg once) of pamidronate (40.7% v 27.6% v 26.8%, P = .049, respectively). No significant difference in rates of hypocalcemia were observed on day 7 (56.8% v 50% v 42.9%, P = .26, respectively) and day 30 (39.1% v 39.0% v 37.5%, P = .50, respectively). CONCLUSION Bisphosphonates were equally efficacious in normalizing serum calcium in patients with HCM. Pamidronate 90 mg was not more efficacious than 60 mg. Rates of refractory hypocalcemia were similar.